The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain

IntroductionPsoriasis is a chronic disease involving the skin, which significantly impacts the quality of life. Disease severity and treatment efficacy (i.e., response) are assessed through the Psoriasis Area and Severity Index (PASI). A PASI 75 response, i.e., an improvement of at least 75% with re...

Full description

Saved in:
Bibliographic Details
Main Authors: Paulina Maravilla-Herrera (Author), María Merino (Author), Santiago Alfonso Zamora (Author), Jesús Balea Filgueiras (Author), José Manuel Carrascosa Carrillo (Author), Olga Delgado Sánchez (Author), Francisco Dolz Sinisterra (Author), Antonio García-Ruiz (Author), Pedro Herranz Pinto (Author), Antonio Manfredi (Author), José Martínez Olmos (Author), Paloma Morales de los Ríos Luna (Author), Lluís Puig (Author), Sandra Ros (Author), Álvaro Hidalgo-Vega (Author)
Format: Book
Published: Frontiers Media S.A., 2023-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_0425efa1f7f34b929bd2f6ccd7239b0c
042 |a dc 
100 1 0 |a Paulina Maravilla-Herrera  |e author 
700 1 0 |a María Merino  |e author 
700 1 0 |a Santiago Alfonso Zamora  |e author 
700 1 0 |a Jesús Balea Filgueiras  |e author 
700 1 0 |a José Manuel Carrascosa Carrillo  |e author 
700 1 0 |a Olga Delgado Sánchez  |e author 
700 1 0 |a Olga Delgado Sánchez  |e author 
700 1 0 |a Francisco Dolz Sinisterra  |e author 
700 1 0 |a Antonio García-Ruiz  |e author 
700 1 0 |a Pedro Herranz Pinto  |e author 
700 1 0 |a Antonio Manfredi  |e author 
700 1 0 |a José Martínez Olmos  |e author 
700 1 0 |a Paloma Morales de los Ríos Luna  |e author 
700 1 0 |a Lluís Puig  |e author 
700 1 0 |a Lluís Puig  |e author 
700 1 0 |a Sandra Ros  |e author 
700 1 0 |a Álvaro Hidalgo-Vega  |e author 
700 1 0 |a Álvaro Hidalgo-Vega  |e author 
245 0 0 |a The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain 
260 |b Frontiers Media S.A.,   |c 2023-01-01T00:00:00Z. 
500 |a 2296-2565 
500 |a 10.3389/fpubh.2023.1000776 
520 |a IntroductionPsoriasis is a chronic disease involving the skin, which significantly impacts the quality of life. Disease severity and treatment efficacy (i.e., response) are assessed through the Psoriasis Area and Severity Index (PASI). A PASI 75 response, i.e., an improvement of at least 75% with respect to the baseline PASI score, has traditionally been used as a therapeutic benchmark in clinical trials. Therapeutic advances have made PASI 90 or PASI 100 responses possible in most patients treated with some biologics. A greater response may generate social value beyond clinical outcomes that would benefit both patients and society.MethodsA 1-year economic model was applied to estimate the impact of having a PASI 75, PASI 90, or PASI 100 response in four areas of analysis (quality of life, activities of daily living, work productivity, and out-of-pocket expenditures) and the social value of having a PASI 90 or PASI 100 response in comparison with a PASI 75 response. A mixed-methods approach based on the scientific literature, a focus group with patient, and an advisory committee with psoriasis stakeholders was used. The model included three different scenarios: having a PASI 90 vs a PASI 75 response; a PASI 100 vs a PASI 90 response; and a PASI 100 vs a PASI 75 response. A sensitivity analysis was included.ResultsThe annual economic impact per patient with moderate-to-severe plaque psoriasis having a PASI 75 response was estimated at Ł 6,139, mainly related to labour productivity losses and quality of life reductions. Having a PASI 90 or a PASI 100 response would reduce this impact to €3,956 or €1,353, respectively. Accordingly, the social value of having a PASI 90 instead of a PASI 75 response was estimated at €2,183, and €4,786 with a PASI 100 response.DiscussionA PASI 90 or PASI 100 response would have a lower economic impact and a greater social value than a PASI 75 response for patients with moderate-to-severe plaque psoriasis. 
546 |a EN 
690 |a social return 
690 |a socioeconomic impact 
690 |a psoriasis 
690 |a Psoriasis Area and Severity Index (PASI) 
690 |a quality of life 
690 |a out-of-pocket (OOP) expenses 
690 |a Public aspects of medicine 
690 |a RA1-1270 
655 7 |a article  |2 local 
786 0 |n Frontiers in Public Health, Vol 11 (2023) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fpubh.2023.1000776/full 
787 0 |n https://doaj.org/toc/2296-2565 
856 4 1 |u https://doaj.org/article/0425efa1f7f34b929bd2f6ccd7239b0c  |z Connect to this object online.